High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
// Mir Alireza Hoda 1,2,* , Anita Rozsas 1,3,* , Elisabeth Lang 2 , Thomas Klikovits 1 , Zoltan Lohinai 3 , Szilvia Torok 3 , Judit Berta 3 , Matyas Bendek 3 , Walter Berger 2 , Balazs Hegedus 1,4 , Walter Klepetko 1 , Ferenc Renyi-Vamos 5 , Michael Grusch 2 , Balazs Dome 1,3,5,6,** and Viktoria Laszlo 1,** 1 Translational Thoracic Oncology Laboratory, Division of Thoracic Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria 2 Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria 3 National Koranyi Institute of Pulmonology, Budapest, Hungary 4 MTA-SE Molecular Oncology Research Group, Hungarian Academy of Sciences, Budapest, Hungary 5 Department of Thoracic Surgery, National Institute of Oncology and Semmelweis University, Budapest, Hungary 6 Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria * These authors share the first authorship ** These authors are co-senior authors of this study Correspondence to: Viktoria Laszlo, email: // Balazs Hegedus, email: // Keywords : activin A, lung adenocarcinoma, biomarker, metastasis, follistatin, Pathology Section Received : November 20, 2015 Accepted : February 09, 2016 Published : February 29, 2016 Abstract Activin A (ActA)/follistatin (FST) signaling has been shown to be deregulated in different tumor types including lung adenocarcinoma (LADC). Here, we report that serum ActA protein levels are significantly elevated in LADC patients (n=64) as compared to controls (n=46, p =0.015). ActA levels also correlated with more advanced disease stage ( p <0.0001) and T ( p =0.0035) and N (p=0.0002) factors. M1 patients had significantly higher ActA levels than M0 patients ( p <0.001). High serum ActA level was associated with poor overall survival ( p <0.0001) and was confirmed as an independent prognostic factor ( p =0.004). Serum FST levels were increased only in female LADC patients (vs. female controls, p=0.031). Two out of five LADC cell lines secreted biologically active ActA, while FST was produced in all of them. Transcripts of both type I and II ActA receptors were detected in all five LADC cell lines. In conclusion, our study does not only suggest that measuring blood ActA levels in LADC patients might improve the prediction of prognosis, but also indicates that this parameter might be a novel non-invasive biomarker for identifying LADC patients with organ metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of Signalling by the Activin Receptor Complex
Attisano, L., Wrana, J. L., Montalvo, E., & Massagué, J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.3.1066 · Cited by 316
Hansen, J., Rinnov, A., Krogh‐Madsen, R., Fischer, C. P., Andreasen, A. S., Berg, R. M. G., Møller, K., Pedersen, B. K., & Plomgaard, P. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2415 · Cited by 71
Cited by
Bauer, J., Emon, M. A. B., Staudacher, J. J., Thomas, A. L., Zessner-Spitzenberg, J., Mancinelli, G., Krett, N., Saif, M. T., & Jung, B. (2020) · Scientific Reports · doi:10.1038/s41598-019-55687-6 · Cited by 133
Hoda, M. A., Dong, Y., Rozsas, A., Klikovits, T., Laszlo, V., Ghanim, B., Stockhammer, P., Ozsvar, J., Jakopovic, M., Samarzija, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.018 · Cited by 27
“Circulating levels of activin A have been investigated in liver disease including cirrhosis [19] and hepatocellular carcinoma [20], as well as in breast [21], prostate [21], ovarian [22], oral [23], oesophageal [24], pancreatic [25], lung cancer [26] and multiple myeloma [27].”
BackgroundSelf-citationThe Patient-Derived Cancer Organoids: Promises and Challenges as Platforms for Cancer Discovery
Bae, J., Choi, Y. S., Cho, G., & Jang, S. J. (2022) · Cancers · doi:10.3390/cancers14092144 · Cited by 27
The many microenvironments of ovarian cancer
Micek, H. M., Visetsouk, M. R., Fleszar, A. J., & Kreeger, P. K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-59038-3_12 · Cited by 14
Metadata
- Authors
- Hoda, M. A., Rozsas, A., Lang, E., Klikovits, T., Lohinai, Z., Torok, S., Berta, J., Bendek, M., Berger, W., Hegedus, B., Klepetko, W., Renyi-Vamos, F., Grusch, M., Dome, B., & Laszlo, V.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-02-29
- Volume
- 7
- Issue
- 12
- Pages
- 13388-13399
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2290778503
- Cited by
- 57
- References
- 2
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.